SPOTLIGHT: Intercell to acquire Iomai

Austria's Intercell is buying Iomai for $189 million in cash and stock. The deal will add Iomai's patch to prevent traveler's diarrhea and an adjuvant for bird flu vaccine that has produced impressive data. Report

Suggested Articles

GSK has formed several collaborations across the globe that will use its AS03 adjuvant to develop vaccines against the novel coronavirus.

Former FDA Commissioner Scott Gottlieb says 40% of the population needs to be vaccinated to achieve COVID-19 herd immunity.

CanSino Bio, Moderna and a collaboration between Oxford Univeristy and AstraZeneca are frontrunners, but they all face hurdles shared and unique.